Proteasome Inhibitors as a Potential Cause of Heart Failure

This publication has 20 references indexed in Scilit:

• Carfilzomib: A second-generation proteasome inhibitor for the treatment of multiple myeloma
  American Journal of Health-System Pharmacy, 2015
• The ubiquitin–proteasome system: opportunities for therapeutic intervention in solid tumors
  Endocrine-Related Cancer, 2015
• Evolution of carfilzomib dose and schedule in patients with multiple myeloma: A historical overview
  Cancer Treatment Reviews, 2014
• Proteasome inhibitors – molecular basis and current perspectives in multiple myeloma
  Journal of Cellular and Molecular Medicine, 2014
• Incidence and Risk of Cardiotoxicity Associated with Bortezomib in the Treatment of Cancer: A Systematic Review and Meta-Analysis
  PLOS ONE, 2014
• Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
  New England Journal of Medicine, 2008
• Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
  New England Journal of Medicine, 2005
• The development of proteasome inhibitors as anticancer drugs
  Cancer Cell, 2004
• Bortezomib (PS-341): A Novel, First-in-Class Proteasome Inhibitor for the Treatment of Multiple Myeloma and Other Cancers
  Cancer Control, 2003
• Proteasome inhibitors as new anticancer drugs
  Current Opinion in Oncology, 2002